Safety and Efficacy of IBI306 in HeFH Patients

NCT04179669 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterozygous Familial Hypercholesterolemia

Interventions

DRUG: IBI306
DRUG: placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.